The Huntington's disease (HD) community was cheered this month by FDA approval of Austedo (deutetrabenazine), the deuterated tetrabenazine analogue from Teva Pharmaceutical Industries Ltd., to treat chorea, the involuntary, random and sudden, twisting and/or writhing movements associated with HD. (See BioWorld Today, April 5, 2017.)